Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Joanne Lee, Susan Swee-Shan Hue, Stephanie Q Ko, Soo Yong Tan, Xin Liu, Louis-Pierre Girard, Esther Hian Li Chan, Sanjay De Mel, Anand Jeyasekharan, Yen Lin Chee, Liang Piu Koh & Li Mei Poon. (2019) Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature. Expert Review of Hematology 12:12, pages 1095-1105.
Read now
Read now
Mia Schmidt-Hansen, Sabine Berendse, Teresa Marafioti & Christopher McNamara. (2017) Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review. Leukemia & Lymphoma 58:10, pages 2403-2418.
Read now
Read now
Catherine Lai, Cliona Grant & Kieron Dunleavy. (2013) Interpreting MYC and BCL2 in diffuse large B-cell lymphoma. Leukemia & Lymphoma 54:10, pages 2091-2092.
Read now
Read now
Articles from other publishers (13)
Madiha Iqbal, Yennifer Gil Castano, Jonas Paludo, Allison Rosenthal, Zhuo Li, Manuel Beltran, Muhamad Alhaj Moustafa, David Inwards, Luis Porrata, Ivana Micallef, Jose C. Villasboas Bisneto, Patrick Johnston, Stephen M. Ansell, Craig Reeder, Hemant Murthy, Vivek Roy, James Foran, Han W Tun, Mohamed A. Kharfan-Dabaja & Ernesto Ayala. (2022) Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 22:2, pages e89-e95.
Crossref
Crossref
Jie Zhu, Yong Yang, Jin Tao, Shu-Lian Wang, Bo Chen, Jian-Rong Dai, Chen Hu, Shu-Nan Qi & Ye-Xiong Li. (2020) Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. Leukemia 34:10, pages 2576-2591.
Crossref
Crossref
Anahita Nosrati, Ahmad Monabati, Alireza Sadeghipour, Fatemeh Radmanesh, Akbar Safaei & Sajjadeh Movahedinia. (2018) MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type. Annals of Hematology 98:1, pages 169-173.
Crossref
Crossref
Allison Rosenthal & Anas Younes. (2017) High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. Blood Reviews 31:2, pages 37-42.
Crossref
Crossref
Alex F. HerreraMatthew MeiLawrence LowHaesook T. KimGabriel K. GriffinJoo Y. SongReid W. MerrymanVictoria BedellChristine PakHeather SunTanya ParisTracey StillerJennifer R. BrownLihua E. BuddeWing C. ChanRobert ChenMatthew S. DavidsArnold S. FreedmanDavid C. FisherEric D. JacobsenCaron A. JacobsonAnn S. LaCasceJoyce Murata-CollinsAuayporn P. NademaneeJoycelynne M. PalmerGerman A. PihanRaju PillaiLeslie PopplewellTanya SiddiqiAliyah R. SohaniJasmine ZainSteven T. RosenLarry W. KwakDavid M. WeinstockStephen J. FormanDennis D. WeisenburgerYoung KimScott J. RodigAmrita KrishnanPhilippe Armand. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. Journal of Clinical Oncology 35:1, pages 24-31.
Crossref
Crossref
Zhihe Liu, Siyun Li, Wei Guo, Yinping Wang, Ming Wang & Ou Bai. (2017)
MYC
Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection
. BioMed Research International 2017, pages 1-7.
Crossref
Crossref
Keisuke Kawamoto, Hiroaki Miyoshi, Noriaki Yoshida, Naoya Nakamura, Koichi Ohshima, Hirohito Sone & Jun Takizawa. (2016)
MYC
translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
. Cancer Science 107:6, pages 853-861.
Crossref
Crossref
M. Testoni, E. Zucca, K.H. Young & F. Bertoni. (2015) Genetic lesions in diffuse large B-cell lymphomas. Annals of Oncology 26:6, pages 1069-1080.
Crossref
Crossref
Jay A. Read, Jean L. Koff, Loretta J. Nastoupil, Jessica N. Williams, Jonathon B. Cohen & Christopher R. Flowers. (2014) Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. Clinical Lymphoma Myeloma and Leukemia 14:6, pages 460-467.e2.
Crossref
Crossref
R. Vaidya & T.E. Witzig. (2014) Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Annals of Oncology 25:11, pages 2124-2133.
Crossref
Crossref
Jonathon B. Cohen, Susan M. Geyer, Gerard Lozanski, Weiqiang Zhao, Nyla A. Heerema, Nathan C. Hall, Veena A. Nagar, Jessica A. Hemminger, Jeffrey A. Jones, Pierluigi Porcu, Beth A. Christian, Robert A. Baiocchi, Kami J. Maddocks, Joseph M. Flynn, Steven M. Devine & Kristie A. Blum. (2014) Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer 120:11, pages 1677-1685.
Crossref
Crossref
Kuangguo Zhou, Danmei Xu, Yang Cao, Jue Wang, Yunfan Yang & Mei Huang. (2014) C-MYC Aberrations as Prognostic Factors in Diffuse Large B-cell Lymphoma: A Meta-Analysis of Epidemiological Studies. PLoS ONE 9:4, pages e95020.
Crossref
Crossref
Pei Lin & L. Jeffrey Medeiros. (2013) The Impact of MYC Rearrangements and ?Double Hit? Abnormalities in Diffuse Large B-Cell Lymphoma. Current Hematologic Malignancy Reports 8:3, pages 243-252.
Crossref
Crossref